Similar articles

• Immunological aspects of candidal vaginitis.

  Hobbs JR, Brigden D, Davidson F, Kahan M, Oates JK. Hobbs JR, et al. Proc R Soc Med. 1977;70 Suppl 4(Suppl 4):11-14. doi: 10.1177/00359157770700S404. Proc R Soc Med. 1977. PMID: 122687 Free PMC article. No abstract available.
• Candidal vaginitis: natural history, predisposing factors and prevention.

  Morton RS, Rashid S. Morton RS, et al. Proc R Soc Med. 1977;70 Suppl 4(Suppl 4):3-6. doi: 10.1177/00359157770700S402. Proc R Soc Med. 1977. PMID: 122691 Free PMC article. No abstract available.
• Risk factors for recurrent vulvovaginal candidiasis.

  Farage MA, Stadler A. Farage MA, et al. Am J Obstet Gynecol. 2005 Mar;192(3):981-2; author reply 982-3. doi: 10.1016/j.ajog.2004.08.020. Am J Obstet Gynecol. 2005. PMID: 15746702 No abstract available.
• [Review of the latest treatments of vulvovaginal mycoses: role of fenticonazole nitrate (Lomexin) in their treatment].

  Cohen J. Cohen J. Contracept Fertil Sex. 1997 May;25(5):396-403. Contracept Fertil Sex. 1997. PMID: 9273113 Review. French.
• Managing patients with vulvovaginal candidiasis.

  Elliott KA. Elliott KA. Nurse Pract. 1998 Mar;23(3):44-6,49-53. Nurse Pract. 1998. PMID: 9560829 Review.